PT100620A - Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem - Google Patents

Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem

Info

Publication number
PT100620A
PT100620A PT100620A PT10062092A PT100620A PT 100620 A PT100620 A PT 100620A PT 100620 A PT100620 A PT 100620A PT 10062092 A PT10062092 A PT 10062092A PT 100620 A PT100620 A PT 100620A
Authority
PT
Portugal
Prior art keywords
alkyl
pharmaceutical compositions
compositions containing
hydrocarbazole
tetra
Prior art date
Application number
PT100620A
Other languages
English (en)
Other versions
PT100620B (pt
Inventor
Alberto Julio Kaumann
Francis David King
Laramie Mary Gaster
Rodney Christopher Young
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT100620(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PT100620A publication Critical patent/PT100620A/pt
Publication of PT100620B publication Critical patent/PT100620B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT100620A 1991-06-26 1992-06-24 Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem PT100620B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments

Publications (2)

Publication Number Publication Date
PT100620A true PT100620A (pt) 1993-09-30
PT100620B PT100620B (pt) 1999-01-29

Family

ID=10697363

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100620A PT100620B (pt) 1991-06-26 1992-06-24 Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem

Country Status (35)

Country Link
US (2) US5464864A (pt)
EP (1) EP0591280B1 (pt)
JP (1) JP3261502B2 (pt)
KR (1) KR100251571B1 (pt)
CN (1) CN1034072C (pt)
AP (1) AP344A (pt)
AT (1) ATE170746T1 (pt)
BR (2) BR9206237A (pt)
CA (1) CA2113726C (pt)
CZ (3) CZ282327B6 (pt)
DE (2) DE10299042I2 (pt)
DK (1) DK0591280T3 (pt)
FI (1) FI103967B (pt)
GB (1) GB9113802D0 (pt)
HK (1) HK1014669A1 (pt)
HU (1) HU218907B (pt)
IE (1) IE922062A1 (pt)
IL (4) IL117105A0 (pt)
LU (1) LU90939I2 (pt)
MA (1) MA22563A1 (pt)
MX (1) MX9203444A (pt)
NL (1) NL300103I2 (pt)
NO (2) NO304774B1 (pt)
NZ (1) NZ243288A (pt)
PL (3) PL169410B1 (pt)
PT (1) PT100620B (pt)
RU (1) RU2137474C1 (pt)
SA (1) SA92130141B1 (pt)
SG (1) SG47877A1 (pt)
SI (1) SI9200125B (pt)
SK (3) SK280906B6 (pt)
TW (1) TW214544B (pt)
UA (1) UA41254C2 (pt)
WO (1) WO1993000086A1 (pt)
ZA (1) ZA924658B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
ES2151993T3 (es) * 1995-06-23 2001-01-16 Lilly Co Eli 1,2,3,4-tetrahidro-9h-carbazoles 6-sustituidos y 10h-ciclohepta(7,6-b)indoles 7-sustituidos.
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
ATE444965T1 (de) 2002-06-21 2009-10-15 Suven Life Sciences Ltd Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
RU2340619C2 (ru) 2002-06-21 2008-12-10 Сувен Лайф Сайенсиз Лимитед Новые тетрациклические арилсульфонилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции
CN102249981A (zh) 2002-11-28 2011-11-23 苏文生命科学有限公司 N-芳基磺酰基-3-氨基烷氧基吲哚
AU2003237599B2 (en) 2002-11-28 2009-06-18 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
AU2003292510B2 (en) 2002-12-18 2009-04-23 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity
RU2448092C2 (ru) * 2006-08-07 2012-04-20 Актелион Фармасьютиклз Лтд Производные (3-амино-1,2,3,4-тетрагидро-9н-карбазол-9-ил)уксусной кислоты
CA2665841C (en) 2006-10-09 2016-04-05 Charleston Laboratories, Inc. Pharmaceutical compositions
AU2008214205B2 (en) 2007-02-11 2014-04-24 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド 薬学的組成物
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US9204906B2 (en) 2009-10-22 2015-12-08 Nuvasive, Inc. Posterior cervical fusion system and techniques
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
AU2012287120B2 (en) 2011-07-22 2017-02-23 The University Of Chicago Treatments for migraine and related disorders
US9394314B2 (en) 2012-12-21 2016-07-19 Map Pharmaceuticals, Inc. 8′-hydroxy-dihydroergotamine compounds and compositions
EP2816030A1 (en) 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
US4172834A (en) * 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
CZ282061B6 (cs) 1997-05-14
US5637611A (en) 1997-06-10
DE10299042I1 (de) 2003-02-20
MA22563A1 (fr) 1992-12-31
SK131993A3 (en) 1994-06-08
BR9206237A (pt) 1995-04-11
AP9200403A0 (en) 1992-07-31
IE922062A1 (en) 1992-12-30
TW214544B (pt) 1993-10-11
IL117104A (en) 1997-09-30
EP0591280B1 (en) 1998-09-09
US5464864A (en) 1995-11-07
CZ282083B6 (cs) 1997-05-14
FI935842A0 (fi) 1993-12-23
CA2113726C (en) 2008-02-19
DK0591280T3 (da) 1999-02-15
HUT68961A (en) 1995-08-28
FI103967B1 (fi) 1999-10-29
DE69226953D1 (de) 1998-10-15
CN1034072C (zh) 1997-02-19
JPH06508827A (ja) 1994-10-06
CZ286193A3 (en) 1994-07-13
UA41254C2 (uk) 2001-09-17
CN1069726A (zh) 1993-03-10
IL117104A0 (en) 1996-06-18
PL169410B1 (pl) 1996-07-31
PT100620B (pt) 1999-01-29
CZ150596A3 (en) 1997-05-14
WO1993000086A1 (en) 1993-01-07
NO2005011I2 (no) 2008-02-11
SG47877A1 (en) 1998-04-17
IL117105A0 (en) 1996-06-18
CZ150696A3 (en) 1997-06-11
ATE170746T1 (de) 1998-09-15
AU652842B2 (en) 1994-09-08
GB9113802D0 (en) 1991-08-14
SK280906B6 (sk) 2000-09-12
KR100251571B1 (ko) 2000-07-01
SI9200125B (en) 2001-12-31
DE69226953T2 (de) 1999-05-12
AP344A (en) 1994-07-05
NL300103I2 (nl) 2003-02-03
SI9200125A (en) 1992-12-31
PL171034B1 (en) 1997-02-28
CZ282327B6 (cs) 1997-06-11
EP0591280A1 (en) 1994-04-13
IL102322A (en) 1997-09-30
NO934800D0 (no) 1993-12-23
RU2137474C1 (ru) 1999-09-20
AU1977592A (en) 1993-01-25
CA2113726A1 (en) 1993-01-07
HU218907B (hu) 2000-12-28
NO934800L (no) 1993-12-23
BR1100460A (pt) 2000-07-18
DE10299042I2 (de) 2005-02-03
LU90939I2 (fr) 2002-09-24
SK280907B6 (sk) 2000-09-12
HK1014669A1 (en) 1999-09-30
JP3261502B2 (ja) 2002-03-04
NO304774B1 (no) 1999-02-15
SA92130141B1 (ar) 2005-12-18
IL117105A (en) 1998-01-04
ZA924658B (en) 1993-12-24
FI935842A (fi) 1993-12-23
IL102322A0 (en) 1993-01-14
PL169392B1 (pl) 1996-07-31
FI103967B (fi) 1999-10-29
NO2005011I1 (no) 2005-05-18
SK280905B6 (sk) 2000-09-12
NZ243288A (en) 1994-09-27
MX9203444A (es) 1993-12-01
NL300103I1 (nl) 2002-12-02

Similar Documents

Publication Publication Date Title
PT100620A (pt) Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
IL95568A0 (en) N-substituted-4-pyrimidinamines and pyrimidinidiamines,process for their preparation and pharmaceutical compositions containing them
HUP0004564A2 (hu) Gasztrokinetikus hatású 3- vagy 4-szubsztituált 4-(aminometil)-piperidin-származékok monociklusos benzamidjai, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0203136A2 (hu) Piperazinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
FI893467A0 (fi) Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi
FI20010083A (fi) P-reseptoriantagonistien synteesissä käytetyt välituotteet ja menetelmä niiden valmistamiseksi
NO179695C (no) Anvendelse av æomega-[4-(2-pyrimidinyl)-1-piperazinylÅalkylå-1H-azol-derivater for fremstilling av medisinske produkter beregnet til behandling av forstyrrelser i kognitive funksjoner
NO173139C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-aminopyrimidinonderivater
NZ221543A (en) 4-aminoquinoline derivatives and pharmaceutical compositions containing such
HUP9802534A2 (hu) Neurotranszmitter újrafelvételt gátló kondenzált tropánszármazékok és előállításuk, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
HU900671D0 (en) Process for preparation of heterociclyc compounds containing fused benzene-rings and nitrogen atom
DE69216293D1 (de) 1,4-Disubstituierte Piperidinderivate, ihre Herstellung und therapeutische Verwendung
DE69418789T2 (de) 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren
BG98216A (en) Benzofuran derivatives
JO2321B1 (en) 4-phenyl-pyridine derivatives
SE9601110D0 (sv) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
RU92016545A (ru) Гетероциклические соединения, способ их получения и фармацевтическая композиция
DK26289D0 (da) Anvendelse af 1,4-disubstitueret piperidinyl til fremstilling af et farmaceutisk praeparat til behandling af insomnia
KR890005036A (ko) 아미드화합물, 이들의 제조방법 및 이들 화합물을 함유하여 위신경기능을 활성화하는 조성물
NO961077D0 (no) Substituerte benzoltienylpiperaziner, deres anvendelse som medikamenter og fremgangsmåter for fremstilling
ES8101045A1 (es) Procedimiento para la preparacion de derivados de acidos pi-rrolidinilsulfamoilbenzoicos sustituidos
ES8606258A1 (es) Procedimiento de preparacion de eteres oximas basicos, y de sus sales de adicion acidas farmaceuticamente aceptables
FI971273A (fi) Fenyylialkyyli-(4-piperidinyyli)bentsoaattijohdannaisia

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930507

FG3A Patent granted, date of granting

Effective date: 19981002

PC3A Transfer or assignment

Free format text: 20011112 VERNALIS LIMITED GB

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20131002